KRAS and non-small cell lung adenocarcinoma: We believe that the proper evaluation of the incidence of KRAS concomitant mutations in the Brazilian advanced non-small cell lung adenocarcinoma population is important for the global effort to understand the significance of KRAS mutations and their outcomes in response to distinct therapies, including the recent KRAS G12C-targeted drug sotorasib.